Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial tested three different doses of an investigational treatment called LEO 152020, plus a placebo (a dummy treatment with no active ingredient), in people with atopic dermatitis (eczema). A total of 216 people started the trial — 61 in the higher dose group, 45 in the middle dose group, 49 in the lower dose group, and 61 in the placebo group. The main thing the trial was measuring was a change in eczema severity using a scoring system called the EASI (Eczema Area and Severity Index), which runs from 0 to 72, where higher numbers mean more severe or widespread eczema. This was measured from the start of the trial to week 16. The reported data shows that all four groups had a reduction in their EASI scores over 16 weeks — meaning their scores went down from where they started. The higher dose group's average score dropped by 9.99 points, the middle dose group by 8.83 points, the lower dose group by 8.87 points, and the placebo group by 9.11 points. These reported figures are notably similar across all groups, including the placebo group. The trial also counted the number of unwanted health events (called adverse events) that occurred during the treatment period. The reported data shows 109 such events in the higher dose group, 67 in the middle dose group, 80 in the lower dose group, and 75 in the placebo group. No further breakdown of these events was reported in the data submitted. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older at the time of screening.
- You have been diagnosed with chronic atopic dermatitis (eczema).
- You have had atopic dermatitis for at least 1 year before the start of the trial.
- In the last 6 months, creams or ointments applied to the skin have not worked well enough to control your eczema, or your doctor has advised that those treatments are not suitable for you.
- Your eczema severity falls within a specific moderate range, as measured by a standard medical scoring tool called EASI (confirm with trial site).
- A doctor's assessment of your eczema severity meets a minimum threshold on a standard rating scale (confirm with trial site).
Who may not be able to join:
- You have taken a specific type of medication called a histidine 4 receptor antagonist (including a drug called LEO 152020) within the last 6 months.
- You have previously tried 3 or more systemic treatments for atopic dermatitis — meaning treatments taken by mouth or injection that work throughout the whole body.
- You are currently pregnant, planning to become pregnant, or are breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Expert, LEO Pharma
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change in EASI From Baseline to Week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.